SUBSCRIBE: eNewsletter
Intra-articular administration of sprifermin statistically increases total femorotibial joint cartilage thickness in individuals with symptomatic radiographic knee osteoarthritis, but the clinical importance and duration of the effect are uncertain, say researchers writing recently in JAMA.
Blood clots can cause critical or lethal problems in patients, and individuals with antiphospholipid syndrome can experience these events at any location in their bodies. However, there’s not a great deal of clarity on which risk factors are most significant for this condition. In this Q&A, we feature a conversation with Eileen J. Lydon, ANP-BC, a rheumatology nurse practitioner at New York University Langone Orthopedic Hospital, who recently spoke on recommendations for treating patients with antiphospholipid syndrome.
Among the most noteworthy in 2019: Treatment of rheumatologic diseases with interleukin inhibitors may raise patients’ risks for serious and opportunistic infections and possibly also cancer, researchers reported in JAMA Network Open in October.
Among the year's most noteworthy findings in rheumatology, includes a systemic review and meta-analysis that provides a better understanding of how common infections and cancer really are in patients treated with interleukin (IL) inhibitors. In this article, Dr. Murray offers his personal perspectives on the findings.
Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.
In this month's rheumatoid arthritis quiz, we focus on contraception, a patient's preference for tapering and the self-management of flares.
Physiotherapy is beneficial in patients with ankylosing spondylitis and while more research is needed, expanding traditional exercise programs to include aerobic and cardiorespiratory components along with patient education may improve outcomes for patients with non-radiographic axial spondyloarthritis as well.
Swedish researchers writing in Arthritis Research & Therapy earlier this year report that more than half (54%) of patients discontinue their first TNFi treatment within five years and those who remain on a TNF inhibitor treatment receive a lower dose.
In this month's psoriatic arthritis quiz, we revisit studies presented at the American College of Rheumatology annual meeting last month. Included here is one that highlights interesting trends in prescribing practices by physicians from different specialties. Which specialty is more likely to prescribe more medications?
Nearly one-quarter of patients with ankylosing spondylitis experienced disease progression over time, with male sex, presence of baseline damage, active disease state, and higher inflammatory markers predictive of spinal progression, while treatment with tumor necrosis factor (TNF) inhibitors slowed the progression rate, say researchers recently writing in Arthritis Care & Research.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
